InvestorsHub Logo
Followers 827
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Friday, 09/22/2017 10:50:59 AM

Friday, September 22, 2017 10:50:59 AM

Post# of 209
AGN reports mixed phase-2b NASH data:

https://finance.yahoo.com/news/data-centaur-phase-2b-clinical-120000624.html

In the patients who remained on treatment for two years, there was no significant difference between CVC and placebo in the composite endpoint – reduction in fibrosis by at least one stage with no worsening of NASH. However, in patients with higher baseline fibrosis scores, patients who received CVC had better outcomes during the two year treatment period.

CVC is the drug AGN obtained in the controversial buyout of Tobira (#msg-125266132).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”